

CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)

RECEIPT OF LETTER FROM THE MINISTRY OF HEALTH

The Board of Directors of Cordlife Group Limited (the "**Company**") refers to its announcements dated 30 November 2023, 13 December 2023 and 15 December 2023 (collectively, the "**Announcements**") relating to, among others:

- (a) the issuance of a notice from the Ministry of Health ("**MOH**") to stop for a period up to six months, the collection, testing, processing and/or storage of any new cord blood and human tissues, or the provision of any new types of tests to patients (the "**Notice**");
- (b) the Company's acceptance of the contents of the Notice; and
- (c) the letter from the MOH directing the Company to give effect to the contents of the Notice.

With reference to the above and inspections conducted by the MOH in November 2023 and December 2023 in connection with the Notice, the Company has on 22 January 2024 received a letter from the MOH providing a list of the potential areas of non-compliance with the Healthcare Services (General) Regulations and the Healthcare Services (Cord Blood Banking Services) Regulations ("**Potential Non-Compliances**") that the MOH has identified based on its inspections.

As stated in the MOH's press release dated 30 November 2023 titled "*Investigation of Cordlife Group Limited for Suboptimal Storage Temperature for Cryopreserved Cord Blood*", in addition to the temperature excursions in the tanks (which was previously disclosed in the Announcements), the MOH had found the following process lapses at the Company:

- (i) the Company's temperature monitoring system failed to send notifications of the temperature excursions in certain tanks to the Company's personnel between February and June 2022;
- (ii) the Company's six-monthly preventative maintenance was not carried out for two tanks in 2022; and
- (iii) the Company implemented a new cord blood processing method in August 2023, which was not properly validated according to approved plan and protocol.

In addition to the above, other Potential Non-Compliances set out in the MOH's letter include, among others, ineffective incident reporting frameworks, inadequate training and competence of staff, and the inappropriate storage of cord blood units.

The Company has been informed that it is required to rectify the Potential Non-Compliances (including the circumstances which had led to the Potential Non-Compliances) by 31 May 2024.

The Company will continue to work closely with the MOH to ensure that all identified Potential Non-Compliances are rectified by the requisite deadline. The Company will also continue to comply with all other statutory requirements, including those found under the Healthcare Services Act 2020 and its subsidiary legislations, as well as the licensing conditions issued to the Company in relation to its licensable healthcare services.

The Company will update its shareholders and the investing public, if there are any material developments in relation to the above, in accordance with the requirements of the SGX-ST listing rules.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Tan Poh Lan
Executive Director and Group CEO
23 January 2024